Blue Earth Diagnostics Highlights Presentations on Fluciclovine F 18 and 18F-Fluciclovine at Upcoming ASTRO Annual Meeting

San Francisco, CA (UroToday.com) -- Blue Earth Diagnostics, a Bracco company focused on molecular imaging diagnostics, announced upcoming presentations at the 2020 American Society for Radiation Oncology (ASTRO) Annual Meeting, from October 23 – 28, 2020, to be held in a virtual format.

Presentations encompass the clinical use of Axumin® (fluciclovine F 18) injection positron emission tomography (PET) in recurrent prostate cancer, including a Late-Breaking Abstract Plenary Session presentation by Emory University. Information about an independent investigational study of 18F-fluciclovine PET in brain metastases will also be presented at the meeting. Details of selected oral and poster presentations by Blue Earth Diagnostics collaborators are listed below.

NOTE: Axumin® (fluciclovine F 18) injection is FDA-approved for PET imaging in men with suspected prostate cancer recurrence based on elevated blood prostate-specific antigen (PSA) levels following prior treatment. Presentations noted by “*” discuss results of investigational studies of an approved product that is not approved by the FDA for the specific use or purpose noted.

HIGHLIGHTED SCIENTIFIC PRESENTATIONS

Monday, October 26, 2020
Axumin (fluciclovine F 18) presentations

Title: LBA 1 Initial Report of a Randomized Trial Comparing Conventional- vs Conventional plus Fluciclovine (18F) PET/CT Imaging-Guided Post-Prostatectomy Radiotherapy for Prostate Cancer
Session Title: PL 01 - Plenary Session
Presenter: Ashesh Jani, MD, FASTRO, Emory University, Atlanta, Ga.
Presentation Time: 1:35 ‒ 1:45 PM ET
Presentation No.: LBA 1

Investigational 18F-fluciclovine presentation

Poster Title: 18F-Fluciclovine PET/CT to Distinguish Radiation Necrosis from Tumor Progression in Brain Metastases Treated with Stereotactic Radiosurgery*
Session Title: PV 05 – Poster Q&A – Session 5
Presenter: Martin C. Tom, MD, Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio
Presentation Time: 4:30 PM ET
Presentation No.: 3587

Wednesday, October 28, 2020
Axumin (fluciclovine F 18) presentations

Poster Title: Advanced Imaging Including the 18-F Fluciclovine PET-CT Is Instrumental In the Salvage Management of Prostate Cancer
Session Title: PV 07 – Poster Q&A – Session 7
Presenter: Max Chiu, MD, Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, Neb.
Presentation Time: 2:00 PM ET
Presentation No.: 4136

Poster Title: The Use of 18F-fluciclovine PET/CT in Prostate Cancer Diagnosis and Therapeutic Decision Making
Session Title: PV 07 – Poster Q&A – Session 7
Presenter: Alexandra Dreyfuss, MD, MS, Department of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pa.,
Presentation Time: 2:00 PM ET
Presentation No.: 4056

Blue Earth Diagnostics invites participants at the 2020 ASTRO Annual Meeting to attend the presentations above and to visit Blue Earth Diagnostics’ Commercial Product Showcase for Axumin (fluciclovine F 18) Injection in the Virtual Exhibit Hall. The company also has a Medical Affairs information booth at ASTRO, where attendees can learn about ongoing clinical trials. For full session details and scientific presentation listings, please see the ASTRO2020 online program.

Source: WIRE, BUSINESS. 2020. "Blue Earth Diagnostics Highlights Presentations On Axumin® (Fluciclovine F 18) And 18F-Fluciclovine At Upcoming ASTRO Annual Meeting". Businesswire.Com



Related Content:

18F-Fluciclovine Positron Emission Tomography in Men with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Planning to Undergo Salvage Radiotherapy: Results from LOCATE - Beyond the Abstract


Prostate Cancer Imaging Is Changing Rapidly – What More Should Be Done with Fluciclovine (Axumin®) PET/CT Imaging?